The CBD industry had massive opportunity just after the government approved the Farm Bill and now after Corona Virus
More on YorkPedia:
- Ensopella AG Company is facing a comprehensive reorientation – RIXX Invest AG
- Annette E. Pietri-Ramirez, MD, a Pediatrician with Med Centro® / Consejo de Salud de PR, Inc.
- Chadi Berjaoui, MD, a Family Physician with Carondelet Medical Group
- Ana Conde-Rosa, MD, an Infectious Disease Specialist with Project Response Testing and Treatment Center
- Akinwumi G. Aladesawe, MD, a Pain Management Specialist with Leading Edge Medical Center
(YorkPedia Editorial):- Los Angeles, May 21, 2020 (Issuewire.com) – 2 Cannabis Stocks to Buy for the CBD Super Rebound
The CBD industry had massive opportunity just after the government approved the Farm Bill in 2018.
Market research firms said this was a $20 billion sector in just a few years, but because of the FDA, the market is just full of lotions and potions leaving retailers without notion.
Aurora Cannabis and Canopy Growth, and smaller companies like CBD Global Sciences amongst others, have launched thousands of brands in the U.S. because CBD is legal. CBDNF : STOCK
CBD is the non-psychedelic version of marijuana associated with health and wellness products. Unfortunately for the market segment, the FDA has a mandate to require testing on food products declassified as a Schedule I drug. CBD falls into this category and the majority of the potential sales boost from CBD is tied into ingestible products like foods, dietary supplements and beverages.
The key here is that the related CBD stocks are now appropriately beaten down for the worse case scenario. The positive news from the coronavirus outbreak is that medical cannabis was considered essential in a sign that the regulators and governments continue to view cannabis products as essential parts of life leading to speculation the U.S. federal government will approve regulation.
CBD Global Sciences Commences Its 6th Year of Planting at Its Strasburg Pharms Subsidiary
CBD Global Sciences Inc. (CSE: CBDN; OTC: CBDNF; Frankfurt: GS3), (“CBD Global” or the “Company”), is pleased to announce the start of the 2020 hemp planting season, at our wholly-owned Colorado subsidiary Strasburg Pharms, has begun. This is the Company’s 6th straight year of Hemp production at our 179-acre site. The Company has brought in additional farming expertise this season and, along with our first year of implementing expanded use of feminized seed, we will also be employing some additional techniques that we believe will greatly expand our yields while at the same time significantly reduce our costs per pound of produced biomass.
“The 2020 growing season has arrived at Strasburg Pharms, Colorado, and we look forward to building on the progress we made with the previous year’s harvests,” commented Brad Wyatt, President and CEO. “We look forward to working with our team to optimize all aspects of cultivation and to deliver on a larger mission of bringing wellness to people so they can live happier and healthier lives.”
In order to meet the growing demand for quality CBD products throughout the US, the Company will be planting in excess of 1.7 million feminized seeds which have been derived from our previous high yielding CBD strains. Hemp with higher potency CBD content reduces the amount of biomass required for CBD extracts allowing the maximum benefit in the production of cannabinoids, terpenes and other beneficial compounds. The biomass will be used to create our CBD products sold under our own brands, Aethics and CannaOil, and also for fulfilling orders for our select white label partners throughout the US and other parts of the world.
ABOUT CBD GLOBAL SCIENCES INC.
CBD Global Sciences Inc., is a vertically integrated hemp-based CBD producer, extractor, and branding investment vehicle which currently owns two product categories, branded under the name AETHICS (www.aethics.com) and CANNAOIL (www.cannaoilshop.com), which include CBD Oil tinctures (liquid products), CBD capsules, CBD topicals and CBD hydration products. CBD Global’s hemp-derived CBD extracts are sold through select distributors, brick and mortar retailers, and online.
CBD Global Sciences, through its wholly owned subsidiary, Strasburg Pharms, grows and operates irrigated land in Colorado that grows hemp with only all-natural Colorado water, soil, sun and nutrients that is NEVER sprayed with pesticides or chemicals. Our genetics are hand selected and maintained to present the best cannabinoid profile with extremely high CBD. The extraction/processing facility, operated by CBD Global, is located approximately 40 minutes from the farm.
For further information, i[email protected]
Charlotte’s Web Earns U.S. Patent for Improved Hemp Variety
(TSX:CWEB, OTCQX:CWBHF) Charlotte’s Web, the company behind the world’s most trusted hemp extract has achieved another milestone in its continued commitment to innovation and consistency in hemp genetics. The Company has earned U.S. utility patent U.S. 10,653,085, its second U.S. patent for hemp genetics. This patent is for ‘CW1AS1’, a new hemp variety created by company co-founder Joel Stanley and Sr. Director of Cultivation R&D Bear Reel. The patent takes Charlotte’s Web’s premier proprietary genetics to the next generation, and builds a strong wall of protection around it, and the products made from it.
“This ‘CW1AS1’ patent gives Charlotte’s Web the highest level of protection for our proprietary genetics and ensures that Charlotte’s Web products will continue to be available to the thousands who use them in a form that is consistent and provides the same user experience time and time again,” said Deanie Elsner, Charlotte’s Web CEO and President.
Patents on hemp genetics are a new frontier, and very few patents in this sector have been issued to date. Charlotte’s Web, the world’s largest vertically integrated hemp company, has been at the forefront of this new frontier in hemp patents and will continue to invest in its breeding program and in the science of hemp to ensure a consistent and high-quality supply is available.
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAS REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION: This news release includes certain “forward-looking statements” under applicable Canadian securities legislation. Forward-looking statements include, but are not limited to, statements with respect to future developments and the business and operations of the Corporation after the CSE listing. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to general business, economic, competitive, political and social uncertainties; and delay or failure to receive board, shareholder or regulatory approvals. Readers should not place undue reliance on forward-looking statements. The Corporation disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
This article was originally published by IssueWire. Read the original article here.
This Press Release was originally published by IssueWire. Read the original article here.